• EDUCATION

  • Chemistry Diploma, University of Munich 2002

  • Chemistry BS with honors, Metropolitan University London 1998



  • ADMISSIONS

  • German Patent Attorney

  • European Patent Attorney



  • OTHER DISTINCTIONS

  • Best Exam Paper B in the European Qualifying Examination (EQE) for the admittance as European Patent Attorney in 2009

Markus Coehn is a partner of the firm Peterreins Schley. His practice emphasizes patent litigation and patent prosecution. On the litigation side, Mr. Coehn has handled opposition cases before the European Patent Office and nullity actions before the German Federal Patent Court and the German Federal Supreme Court as well as infringement litigations before German District Courts.

Recent victories include an infringement case before the District Court Duesseldorf in the field of polymers as well as the revocation of a polymer-related road-block patent before the EPO’s Technical Board of Appeal. Other notable successful cases include the defense of a patent regarding electrically conductive engineering plastics before the Federal Supreme Court as well as the revocation of several patents relating to drug-eluting medical devices and agrochemicals before the EPO.

On the prosecution side, Mr. Coehn has prosecuted patents relating to pharmaceuticals at all stages of drug development (drug discovery and lead optimization, medical indication, polymorph, formulation, and dosage patents), medical devices, biotech inventions and high-performance polymers. His practice also includes opinion work, freedom-to-operate analyses, and the prosecution of supplementary protection certificates (SPCs).

Before starting at Peterreins Schley, Mr. Coehn was a partner at Fish & Richardson P.C. Before joining Fish & Richardson P.C., he worked at the IP boutique Bardehle Pagenberg. Prior to his law career, Mr. Coehn worked as research assistant at the University of Munich developing antibiotics against Methicillin-resistant Staphylococcus aureus (MRSA).


SELECTED PUBLICATIONS:

  • Analysis: How the Brüstle ruling has changed the law. Managing Intellectual Property, MIP Issue 2011 Oct 19.
  • “Annotation to the Federal Supreme Court decision Olanzapin” in GRUR 2009, 382-389
  • “Annotation to the decision I-2 W 47/07 of the Upper District Court Duesseldorf– Olanzapin” in Mitt.PA 2008, 335-337
  • “European Case Law on Diagnostic Methods: ‘The Opinion G 1/04′” in GRUR Int 2006, 640-645
  • “European Case Law on Diagnostic Methods” in sic! 2006, 351-356

PETERREINS SCHLEY
Patent- und Rechtsanwälte

info@ps-patent.com